高視醫療(02407.HK):獲納入滬港通及深港通的合資格股份
格隆匯3月13日丨高視醫療(02407.HK)宣佈,根據上海證券交易所及深圳證券交易所刊發的公吿,公司股份獲納入為滬港通計劃及深港通計劃(統稱為"滬港通及深港通")相應股票名單的合資格股份,兩者均自2023年3月13日起生效。
董事認為,公司股份獲納入滬港通及深港通的交易機制,有助於擴大投資者基礎,觸達更廣泛的投資者羣體及增加公司股份的交易流動性,從而實現投資的價值,同時進一步提高其品牌知名度。與此同時,公司可通過資本市場與中國大陸的客户、合作伙伴及投資者們擴大互動基礎,與他們共享公司的成長軌跡及日後的進一步成功。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.